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ported in Table. In ERACI IV MACCE at 1 year was 2.2%, duplicating
this number up to 5.8% at 20 months, although compared to ERACI III,
ERACI IV has lower incidence of MACCE (p<0.001), the same outcome
was seen in diabetics (5.8% vs 25.5%, ERACI IV vs ERACI III respec-
tively, p<0.001) and non-diabetics (5.8% vs 12.4%, respectively p<
0.02)
Table20 months outcome ERACI III-DES ERACI IV-FRB2 p valueN patients 225 225 NADeath 7 (3.1%) 4 (1.8%) 0.54Acute myocardial
infarction (MI)10 (4.4%) 2 (0.9%) 0.01Non-fatal
cerebrovascular
accident (CVA)7 (3.1%) 0 (0.0%) 0.02Death/MI/CVA 21 (9.3%) 6 (2.7%) 0.003Unplanned
revascularization26 (11.6%) 8 (3.6%) 0.001MACCE 38 (16.9%) 13 (5.8%) <0.001Stent thrombosis
(ARC deﬁnition)7 (3.1%) 2 (0.9%) 0.17CONCLUSIONS At 20 þ/- 4 months this multicenter prospective reg-
istry showed that Firebird 2 stent used in complex lesions has a
remarkable low incidence of MACCE and other endpoints. Longer
follow-up is guaranteed to assess if these numbers remains over time.
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BACKGROUND The Svelte (New Providence, NJ) sirolimus-eluting
coronary stent utilizing a bioresorbable amino acid-based (PEA) drug
carrier is a novel stent-on-a-wire Integrated Delivery System (IDS)
consisting of a low-compliant balloon with balloon control bands
(BCBs) afﬁxed to a 0.014” integrated steerable wire with shapeable
tip. The IDS is low-proﬁle and speciﬁcally designed for use with the
transradial approach, ’slender’ PCI and direct stenting. The DIRECT I
ﬁrst-in-human study was designed to evaluate the feasibility of the
Svelte drug-eluting stent IDS.
METHODS Thirty patients with symptomatic ischemic heart disease
and a single de novo native coronary lesion suitable for percutaneous
coronary intervention were prospectively enrolled at 4 New Zealand
sites. Lesion length had to be <23 mm and the vessel reference
diameter 2.5-3.5 mm. The primary safety endpoint was 6-month target
vessel failure (TVF), deﬁned as the composite of death, target vessel
MI or clinically-driven target vessel revascularization (TLR). The pri-
mary efﬁcacy endpoint was 6-month angiographic in-stent late lumen
loss (LLL). All patients were scheduled to receive angiographic and
IVUS follow-up at baseline and 6-months, with 15 patients addition-
ally undergoing OCT analysis at the same time points. All angio-
graphic and clinical data were reviewed and adjudicated by an
independent core lab and DSMB at all reported time points.
RESULTS Twenty-nine of 30 enrolled patients completed 6-month
follow-up. Angiographic in-stent LLL was 0.22þ0.27 mm at 6-
months. Other 6-month follow-up included IVUS assessed neo-
intimal volume of 3.3þ 4.4mm3 and volume obstruction of 2.7þ4.5%.
OCT revealed 98þ4% strut coverage at a depth of 0.12þ0.06 mm.
Through 36-month followup, no patient has experienced stent
thrombosis, MACE or TVF.DIRECT First-In-Human Study 36-Mo. Follow-Up Patients (n[30)Device Success 29/30 (97%)All Death 0/30 (0%)All Myocardial Infarction 0/30 (0%)TLR, Clinically-Driven 0/30 (0%)TVR, Clinically-Driven 0/30 (0%)MACE 0/30 (0%)TVF, Angiographically-Driven 2/30 (7%)Stent Thrombosis, All Time Points 0/30 (0%)CONCLUSIONS This ﬁrst-in-human feasibility study demonstrated
minimal in-stent proliferation by angiography and conﬁrmed by IVUS,
along with near complete strut coverage by OCT. The concordant
excellent clinical outcomes, including no stent thrombosis, suggest
that the Svelte drug-eluting coronary stent IDS warrants further
evaluation. The novel approach to drug delivery may lessen the po-
tential side effects of impaired endothelial recovery, ﬁbrin deposition,
burst drug release and luminal stent strut drug residue sometimes
associated with durable polymer technologies, while direct stenting
with the IDS also minimizes procedural time and adjunctive product
use.
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BACKGROUND There are limited data on the clinical outcomes of
diabetic patients treated with bioresorbable scaffolds (BRS). The aim
of the present analysis is to compare the occurrence of clinical
events in diabetics treated with the Absorb bioresorbable vascular
scaffold (Absorb BVS; Abbott Vascular, Santa Clara, CA) versus
everolimus-eluting metal stents (EES; XIENCE; Abbott Vascular,
Santa Clara, CA).
METHODS The present study included 812 patients in the ABSORB
EXTEND study in which a total of 215 diabetic patients were treated
with Absorb BVS. In addition, 882 diabetic patients treated with EES
in pooled data from the SPIRIT clinical program (SPIRIT II [A Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary Stent Sys-
tem], SPIRIT III [Clinical Trial of the XIENCE V Everolimus Eluting
Coronary Stent System (EECSS)], SPIRIT IV Clinical Trial [Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary Stent Sys-
tem] and XIENCE V USA) were used for comparison by applying pro-
pensity score matching using 29 different variables (217 pairs).
The primary endpoint was major adverse cardiac events (MACE),
including cardiac death, myocardial infarction, and target lesion
revascularization.
RESULTS After propensity score matching, the baseline clinical
characteristics were similar in Absorb BVS and EES groups. As shown
in Figure 1 and Table 1, diabetic patients treated with the BRS had a
similar incidence of MACE compared with diabetics treated with EES
(5.7% vs. 5.6%, respectively; HR 0.99; 0.44-2.20; P¼0.98) after 393
days of follow-up.
